Confo Therapeutics, a pioneering force in drug discovery, has successfully secured $60 million in funding to advance its groundbreaking technology focused on G protein-coupled receptors (GPCRs). This unique platform stabilizes functional conformations of GPCRs, enabling the identification of previously elusive drug targets. With this significant investment, Confo aims to bolster its multi-indication pipeline of drug candidates. The potential impact of this funding is considerable, as it may significantly enhance therapeutic outcomes for patients suffering from serious illnesses that currently lack effective disease-modifying treatments. Established in 2015 as a spin-off from Vrije Universiteit Brussel (VUB) and VIB, Confo Therapeutics draws on a wealth of scientific expertise and innovation from Belgium's rich life sciences ecosystem. The funding round has attracted a diverse array of international investors focused on life sciences, affirming confidence in the company’s vision and mission. With a distinguished team comprising seasoned entrepreneurs and prominent scientists from successful biopharmaceutical firms, Confo Therapeutics is poised to make significant strides in its research and development efforts. This latest round of funding will facilitate the acceleration of lead candidates into clinical trials, ultimately aiming to bring transformative therapies to patients in dire need. For more information about Confo Therapeutics and their innovative approach to drug discovery, visit www.confotherapeutics.com.

Confo Therapeutics Secures $60 Million in Series B Funding for Breakthrough GPCR Drug Targeting Technology
Get the full Confo Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Centricity WealthTech
Founded in January 2022, Centricity helps empower finance and investment professionals aspiring to establish their independent practices. The platform aims to deliver a comprehensive SAAS based investment management platform including digital transactional capabilities for a diversified product suite. Wealth management professionals prefer focusing on their clients’ interests and not their employers ever-changing priorities. Also, clients want stability and not a relentless institutional product push. We are looking to bring in consistency of the family office experience for a spectrum of investors across emerging affluent, affluent and high net worth categories. We are boutique by design and an institution by default.
$30.0M Series a
today

MigmaAI
Create, design and send on-brand emails in seconds.
$330.0K Pre-seed
today

Multiverse
Multiverse is the upskilling platform for AI and tech adoption. We’ve built a new model for transforming today’s workforce by combining expert human coaching with AI. Our learning drives real business impact and helps organisations close critical skills gaps - especially in data, AI and all things tech. We’ve already partnered with over 1,500 global organisations to transform their workforce through tech skills. Trusted by Microsoft, Mars, John Lewis Partnership and many more to upskill their team and unlock people’s potential and output. In 2022, we raised our $220m Series D funding - one of the largest venture rounds in EdTech history. We’re proud to be backed by some of the world’s biggest investors, including General Catalyst, Lightspeed Venture Partners and StepStone Group.
$70.0M Unknown
today

SWELL Sculpture Festival
SWELL Sculpture Festival (SWELL) is a multifaceted arts organisation that connects people, art, and place, based in Currumbin, Gold Coast, Queensland. Since 2003 SWELL has exhibited 873 Sculptures in the main exhibition on Currumbin Beach with a portfolio value worth $15.5M.
$5.5K Grant
today

Parcel Health
Healthcare and pharmacies' supply chain runs on expensive plastic. Billions of units of disposable, single-use supplies and packaging — most of it never questioned, never redesigned, never replaced. Paid for at a premium to budgets and to the environment. Until now. Parcel Health is reimagining healthcare supplies, creating products that can protect people and preserve the planet, all at an affordable price point. Tully Tube® is the world's first and only paper pill bottle that meets U.S. regulatory requirements. It is trusted by leading hospital health-systems like Dartmouth-Hitchcock Health System, Allegheny Health Network, and Wellstar Health System. This is just the beginning. Parcel Health is building a future where healthcare supplies are safer for patients, better for the planet, and easier on budgets.
$1.2M Seed
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() equipifi United States | Series b | $34.0M | today |
| 2 | ![]() ANELLO Photonics United States | Series b | $25.0M | 1d ago |
| 3 | ![]() Forest United States | Series b | $23.0M | 1d ago |
| 4 | ![]() EnteroBiotix United Kingdom | Series b | $23.9M | 1d ago |
| 5 | ![]() Fractile United Kingdom | Series b | $220.0M | 1d ago |




